CN115074321A - 一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 - Google Patents
一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 Download PDFInfo
- Publication number
- CN115074321A CN115074321A CN202210773047.6A CN202210773047A CN115074321A CN 115074321 A CN115074321 A CN 115074321A CN 202210773047 A CN202210773047 A CN 202210773047A CN 115074321 A CN115074321 A CN 115074321A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- serum
- stem cells
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 53
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000001737 promoting effect Effects 0.000 title claims abstract description 20
- 108090000695 Cytokines Proteins 0.000 claims abstract description 22
- 102000004127 Cytokines Human genes 0.000 claims abstract description 21
- 239000004017 serum-free culture medium Substances 0.000 claims abstract description 20
- 230000004936 stimulating effect Effects 0.000 claims abstract description 20
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 239000012228 culture supernatant Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 47
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 239000012679 serum free medium Substances 0.000 claims description 11
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 claims description 10
- 241000388430 Tara Species 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 210000003954 umbilical cord Anatomy 0.000 claims description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 235000019192 riboflavin Nutrition 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 239000002151 riboflavin Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 6
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- 102000038379 digestive enzymes Human genes 0.000 claims description 6
- 108091007734 digestive enzymes Proteins 0.000 claims description 6
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 230000004217 heart function Effects 0.000 claims description 3
- 229940116978 human epidermal growth factor Drugs 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 3
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- 108010053835 Catalase Proteins 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- 239000004395 L-leucine Substances 0.000 claims description 2
- 235000019454 L-leucine Nutrition 0.000 claims description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- FBKIASNRVHFWNA-USHJOAKVSA-N O.O.[Na].[Na].N[C@@H](Cc1ccc(O)cc1)C(O)=O Chemical compound O.O.[Na].[Na].N[C@@H](Cc1ccc(O)cc1)C(O)=O FBKIASNRVHFWNA-USHJOAKVSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 102000016938 Catalase Human genes 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 description 24
- 230000001146 hypoxic effect Effects 0.000 description 20
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 18
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 17
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 210000003556 vascular endothelial cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 102000009088 Angiopoietin-1 Human genes 0.000 description 3
- 108010048154 Angiopoietin-1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000009764 endothelial cell sprouting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种间充质干细胞(MSC)来源的促血管新生的制剂及其制备方法,所述制备方法包括如下步骤:步骤(1),在无血清培养基中稳定培养间充质干细胞;步骤(2),使用细胞因子刺激制剂继续刺激培养所述稳定培养的间充质干细胞;步骤(3),收集经步骤(2)培养的间充质干细胞的培养上清液;步骤(4),浓缩所述的培养上清液得浓缩上清液,即为所述促血管新生制剂。
Description
技术领域
本发明属于医药生物技术领域,具体的,涉及一种间充质干细胞(MSC)来源的促血管新生的制剂及其制备方法。
背景技术
间充质干细胞(mesenchymal stem cells,MSC)是一群来自中胚层,具有向软骨细胞,骨骼细胞和脂肪细胞等多种终末端细胞分化的能力的成体干细胞,MSC来源丰富,广泛存在于骨髓组织、脐带组织、胎盘组织和脂肪组织中。MSC具有强大的旁分泌能力,有研究显示正常培养的MSC可以分泌超过200余种细胞生长因子作用于靶细胞上,实现特点生理功能,因此MSC免疫调节、促血管新生、促受损组织再生、支持造血等重要的生理功能,目前已经作为一个新药被多个国家批准上市,用于移植物抗宿主疾病(GVHD)、溃疡性结肠炎、克罗恩病、骨关节炎(OA)、心肌梗塞后心脏功能恢复等疾病上。
间充质干细胞(MSC)分泌的200余种细胞因子中,有一大类具有显著的促血管新生的能力,被称为血管活性因子,包括血管内皮细胞生长因子(vascular endothelialgrowth factor,VEGF)、血管生成素(angiopoietin,Ang)、碱性成纤维细胞生长因子(basicfibroblast grow factor,bFGF)等。
血管内皮细胞生长因子是血管新生过程中最重要的细胞生长因子,VEGF在体外可以直接刺激血管内皮细胞的增殖和迁移,在体内血管新生的模型中可以看到VEGF是一种强有力的血管新生诱导因子,此外VEGF还具有抑制血管内皮细胞凋亡的作用,在整个血管新生过程中是最重要刺激因子。
血管生成素是一类分泌型细胞因子,在血管重塑、胚胎血管发育中起重要的作用,血管生成素家族成员有4个,包括Ang-1、Ang-2、Ang-3、Ang-4,其中Ang-1起主要生理作用,Ang-1通过激活其受体酪氨酸激酶tie-2来抑制血管内皮细胞凋亡、促进血管内皮细胞生存,并进一步促进血管内皮细胞出芽、迁移和趋化形成新的血管,同时稳定新生血管结构,防止管壁渗漏等重要的生理作用。
碱性成纤维细胞生长因子是一种重要的促细胞有丝分裂因子和血管生成因子,对来源于中胚层和神经外胚层的多种类型细胞具有广泛的生物学活性,能促进细胞增殖、生长、分化,促血管新生,改善细胞生长微环境,促进受损组织的血管再生能力,能促进血管内皮细胞以及血管平滑肌细胞的生长,促进新生毛细血管形成,增加组织中毛细血管数量以及血流供应,为组织修复提供所需的氧气和营养成分。
MSC可以从脐带、胎盘、脂肪、骨髓等多个组织中分离,不同组织中分离的MSC具有独特的生理学功能。在所有的器官和组织中,脂肪组织的氧分压几乎是最高的,可以达到40-60mmHg,脂肪细胞对缺氧及其敏感,因此从脂肪组织中分离的脂肪间充质干细胞(ADSC)相比骨髓或脐带组织来源的MSC具有更强的促血管新生能力,但是骨髓和脂肪间充质干细胞一般需要从成年人中提取,其提取过程受年龄限制,对供者具有一定损伤。相比于成体间充质干细胞,脐带间充质干细胞发育更加原始,细胞增殖能力强,样本采集对无损伤,更适合后期临床应用。但同样的也存在一定的问题,简要而言,成体间充质干细胞(脂肪间充质干细胞)和脐带间充质干细胞的在临床应用中的缺点大致为:
1,自体脂肪间充质干细胞(ADSC)使用前需先采集患者脂肪组织,对患者来说是一种侵害;
2,异体脂肪间充质干细胞(ADSC)大多采集于成年供者,ADSC体外扩增能力有限,增殖能力弱于脐带间充质干细胞(UC-MSC);
3,正常培养条件下的脐带间充质干细胞(UC-MSC)表达并分泌的促血管新生相关细胞因子能力有限,因为细胞因子分泌量不足带来治疗效果不佳。
4,正常培养条件下的脐带间充质干细胞(UC-MSC)局部移植到患者缺血组织中因组织的缺氧环境而造成存活能力不高,直接影响后期治疗效果。
基于此,提出本发明。
发明内容
本发明首先涉及一种间充质干细胞(MSC)来源的促血管新生制剂的制备方法,所述方法包括如下步骤:
步骤(1),在无血清培养基中稳定培养间充质干细胞;
步骤(2),使用细胞因子刺激制剂继续刺激培养所述稳定培养的间充质干细胞;
步骤(3),收集经步骤(2)培养的间充质干细胞的培养上清液;
步骤(4),浓缩所述的培养上清液得浓缩上清液,即为所述促血管新生制剂。
所述的无血清培养基含量(mg/L)如下表所示:
成分 | 含量 | 成分 | 含量 | 成分 | 含量 |
L-精氨酸 | 100 | L-谷氨酸 | 10 | L-天门冬酰胺 | 75 |
L-天门冬氨酸 | 30 | L-组氨酸 | 30 | 甘氨酸 | 5 |
L-谷氨酰胺 | 500 | L-苯丙氨酸 | 30 | L-脯氨酸 | 10 |
L-异亮氨酸 | 25 | L-蛋氨酸 | 10 | L-赖氨酸盐酸 | 60 |
L-亮氨酸 | 75 | L-丝氨酸 | 45 | L-色氨酸 | 15 |
L-苏氨酸 | 10 | L-缬氨酸 | 10 | 亚硒酸钠 | 35.0 |
葡萄糖 | 1000 | 人血清白蛋白 | 1000 | 丙酮酸钠 | 550 |
L-胱氨酸二盐酸 | 75 | 二水L-酪氨酸二钠 | 144 | 过氧化氢酶 | 20 |
维生素C | 0.704 | 胰岛素 | 20 | 胆固醇 | 20 |
β-巯基乙醇 | 4.0 | 人转铁蛋白 | 5 | 纤粘连蛋白 | 5 |
1%二巯基乙醇溶液 | 1.0ml/L | 乙醇胺 | 1 | 地塞米松 | 0.005 |
SnCl<sub>2</sub>·2H<sub>2</sub>O | 0.0001 | FeSO<sub>4</sub>·7H<sub>2</sub>O | 1.6 | 对羟基苯甲酸 | 0.5 |
CoCl<sub>2</sub>·6H<sub>2</sub>O | 0.001 | CuSO<sub>4</sub>·5H<sub>2</sub>O | 0.0005 | 亚油酸 | 0.01 |
Na<sub>2</sub>SeO<sub>3</sub> | 0.002 | ZnSO<sub>4</sub>·7H<sub>2</sub>O | 0.6 | NaSiO<sub>3</sub>·9H<sub>2</sub>O | 0.01 |
Na<sub>3</sub>VO<sub>4</sub>·12H<sub>2</sub>O | 0.0005 | Ni(NO3)<sub>2</sub>·6H<sub>2</sub>O | 0.00002 | 余量为水 |
优选的,所述的无血清培养基中,进一步包含:
重组人成纤维细胞生长因子(FGF),10mg/L;
重组人转化因子β(TGF-b),0.1mg/L;
重组人表皮生长因子(EGF),0.1mg/L。
所述的细胞因子刺激制剂为:在所述无血清培养基添加刺激因子配制,刺激因子由以下单个或多个组合而成:
全反式维甲酸(TARA),0.1mM-50mM,优选为1uM-200uM;
核黄素(VB2),0.05mM-50mM,优选为1uM-10uM;
抗坏血酸(Vc),0.1mM-100mM,优选为10uM-100uM;
维生素A(Va),0.01mM-50mM,优选为0.01uM-0.1uM;
辅酶Q10,0.05mM-50mM,优选为0.1uM-1uM。
步骤(1)所述的稳定培养间充质干细胞的方法为:
MSC长至90%融合度时使用温和消化酶消化成单细胞,以活细胞数量按1-10*105/cm2的密度接种于经TC处理的培养皿中,使用无血清培养基置于低氧(0.5%-10%)培养箱中培养24小时;
步骤(2)所述的刺激培养为:
1)细胞长至50%-70%融合度时,更换为预处理培养基(0.1-0.5ml/cm2);
2)更换为预处理培养基后置于低氧(0.5%-10%)培养箱中继续培养48小时;
步骤(4)所述的浓缩所述的培养上清液为:使用超滤管离心浓缩5倍;
本发明还涉及使用所述方法制备得到的促血管新生制剂。
本发明还涉及所述方法和所述的促血管新生制剂在制备药物中的应用,所述的药物包括但不限于:治疗移植物抗宿主疾病的药物、治疗抗溃疡性结肠炎的药物、治疗克罗恩病的药物、治疗骨关节炎的药物、用于心肌梗塞后心脏功能恢复的药物。
本发明的有益效果在于:
1、针对目前MSC治疗缺血性疾病存在的缺点,本发明通过体外预刺激的方法激活MSC的生物学活性;
2、使用本发明的方法激活的MSC,一方面能适应患者缺血组织中的缺氧环境,提供其在病灶组织中的存活率,另一方面能大量表达并分泌多种促血管新生的细胞因子,可以有效促进缺血组织的血管新生能力,加速缺血组织中毛细血管新生速度,加快侧支循环重建,从而达到治疗组织缺血的目的。
附图说明
图1、各组UC-MSC细胞的促血管生长因子表达量。
图2、各组UC-MSC细胞促血管生长因子分泌量。
图3、HUVEC细胞成血管实验(图中标尺为100um)。
图4、HUVEC细胞迁移实验(图中标尺为100um)。
图5、RA对UC-MSC细胞活性影响(因为纵轴数值偏小,导致100和200近似重合)。
图6、血管新生相关基因表达量。
图7、各组培养细胞显微照片。
图8、各组UC-MSC细胞促血管生长因子VEGF bFGF分泌量
具体实施方式
以下实施例中使用的无血清培养基各原料的浓度如下表1所示(以下各成分浓度单位若无特别说明,均为mg/L):
表1,无血清培养基成分表
所述的无血清中进一步包含:
重组人成纤维细胞生长因子(FGF)(peprotech,货号:100-18B-50),10mg/L
重组人转化因子β(TGF-b)(peprotech,货号:100-21-100),0.1mg/L
重组人表皮生长因子(EGF)(peprotech,货号:AF-100-15-50),0.1mg/L。
以下实施例所用的预处理培养基的配置过程为:由无血清培养基添加刺激因子配制,刺激因子由以下单个或多个组合而成:
全反式维甲酸(TARA),1uM-200uM(Sigma R2625),
核黄素(VB2),1uM-10uM(Sigma 9504),
抗坏血酸(Vc),10uM-100uM(Sigma A92902),
维生素A(Va),0.01uM-0.1uM(Sigma R7632),
辅酶Q10,0.1uM-1uM(Sigma 9538)。
其他试剂耗材为常规分子生物学或细胞生物学试剂耗材。
实施例1、UC-MSC细胞的传代培养及预处理
1、脐带间充质干细胞(UC-MSC),使用无血清培养基正常培养到P4代;
2,P4代UC-MSC长至90%融合度时使用温和消化酶(北京友康恒业生物科技有限公司NC1004.1)消化成单细胞,计数后离心(1500rpm*5min),去上清;
3,根据计数结果,以活细胞数量按1-10*105/cm2的密度接种于经TC(TissueCulture,指器皿经过表面的改性处理,适合贴壁细胞的培养)处理的培养皿中,使用无血清培养基置于低氧(0.5%-10%)培养箱中培养24小时;
4,待细胞长至50%-70%融合度时,更换为预处理培养基(0.1-0.5ml/cm2);
5,更换为预处理培养基后置于低氧(0.5%-10%)培养箱中继续培养48小时;
6,培养48小时后收集细胞上清液用于后续检测,使用温和消化酶(北京友康恒业生物科技有限公司NC1004.1)消化细胞,计数后离心(1500rpm*5min)去上清,使用GMP级冻存液(北京友康恒业生物科技有限公司NC1010)冻存细胞备用。
实施例2、不同条件下UC-MSC促血管新生相关细胞因子基因表达
1,选取P3~P5代UC-MSC(优选为P4代),消化后以2*105/cm2密度接种于6孔板中,使用无血清培养基培养,随机分为3组:
正常组置于普通二氧化碳培养箱中(5%CO2+20%O2)培养,
低氧组和预处理组置于低氧培养箱中培养(5%CO2+0.5%-10%O2);
2,24小时后更换培养基,每孔2ml,正常组使用无血清培养基正常培养,低氧组使用无血清培养基于低氧培养箱中培养,预处理组使用预处理培养基于低氧培养箱中培养;各组均继续培养48小时;
3,48小时后收集各组的细胞因子于-20℃冷冻保存,细胞使用PBS清洗后使用Trizol(Thermo 15596026)重悬,提取细胞中总RNA并逆转录为cDNA于-20℃保存(天根KR106);
4,通过QPCR(Promega A6002)检测各组细胞中促血管新生相关因子的表达量,包括血管内皮细胞生长因子(VEGF)、血管生成素1(Ang-1)、碱性成纤维细胞生长因子(bFGF),引物序列如表2所示,结果如图1所示;
表2、促血管新生相关因子的检测引物
5,收集的细胞因子上清液使用Ellisa试剂盒检测各组细胞分泌的促血管新生的细胞因子,包括血管内皮细胞生长因子(VEGF)(欣博盛EHC108)、血管生成素1(Ang-1)(酶免MM-0001H2)和碱性成纤维细胞生长因子(bFGF)(酶免MM-0151H2),结果如图2所示。
结果显示,预处理组的各个促血管新生的细胞因子尤其是VEGF的表达和分泌量有显著的提升。
实施例3、人血管内皮细胞功能检测
1,选取P4代UC-MSC,消化后以2*105/cm2密度接种于6孔板中,使用无血清培养基培养,随机分为3组:
正常组置于普通二氧化碳培养箱中(5%CO2+20%O2)培养,
低氧组和预处理组置于低氧培养箱中培养(5%CO2+0.5%-10%O2);
2,24小时后更换培养基,每孔2ml,正常组使用无血清培养基正常培养、低氧组使用无血清培养基于低氧培养箱中培养、预处理组使用预处理培养基于低氧培养箱中培养,各组均继续培养48小时;
3,收集含细胞因子的细胞培养上清液,经超滤管离心浓缩5倍(MilliporeUFC900396),冷藏备用;
4,取Matrigel(BD 356234)胶使用DMEM培养基按1:2.5比例稀释后铺到96孔板中,每孔40ul,置于37℃培养箱中30min使其凝固;
5,取P4代人脐带静脉血管内皮细胞(HUVEC)(广州赛业生物科技有限公司HUVEC-20001),温和消化酶消化成单细胞后接种到96孔板中的Matrigel胶上,每孔2*104个细胞,并加入浓缩后的细胞因子上清液,每孔100ul,置于37℃常氧培养箱中培养24h,观察HUVEC成血管能力,结果如图3所示;
6,取P4代人脐带静脉血管内皮细胞(HUVEC)(广州赛业生物科技有限公司HUVEC-20001),温和消化酶消化成单细胞后接种到预置伤口愈合插件培养皿(Ibidi 80206)中,细胞密度为5*105/ml,每孔接种70ul,24小时后去掉插件的中间隔板,培养皿中加入2ml浓缩后的细胞因子上清液,置于37℃常氧培养箱中培养48h,观察HUVEC的迁移能力,结果如图4所示。
实施例4、全反式维甲酸预处理对UC-MSC细胞活性影响
1、选取P4代UC-MSC消化后以1*104/cm2密度接种于96孔板中,使用无血清培养基置于低氧(0.5%-10%)培养箱中培养过夜;
2、24小时后更换为0、5、10、50、100、200uM浓度的全反式维甲酸预处理培养基(0.3-0.6ml/cm2);
3、连续培养5天,评估Day1、Day2、Day3、Day4、Day5细胞增殖毒性,使用CCK8细胞增殖毒性检测-试剂盒(日本同仁化学CK04),每孔加入10ul的CCK8溶液;
4、将板置于普通二氧化碳培养箱中(5%CO2+20%O2)培养4小时,在一定时间内用全波长酶标仪(Thermo Multiskan Sky)检测OD值,结果如图5。
结果显示,全反式维甲酸(TARA)有明显毒性,10uM及以上可见,实际使用浓度应降低,参考常用的诱导分化使用浓度2-5uM。
实施例5、不同刺激因子对UC-MSC促血管新生相关细胞因子基因表达
1,选取P5代UC-MSC,消化后以2*105/cm2密度接种于6孔板中,使用无血清培养基培养,随机分为5组:
正常组置于普通二氧化碳培养箱中(5%CO2+20%O2)培养,
低氧组和预处理组置于低氧培养箱中培养(5%CO2+0.5%-10%O2);
2,24小时后更换培养基,每孔2ml,正常组使用无血清培养基正常培养,低氧组使用无血清培养基于低氧培养箱中培养,预处理组分别使用10uM全反式维甲酸(TARA)、5uM核黄素(VB2)、50uM抗坏血酸(Vc)三种刺激因子预处理培养基于低氧培养箱中培养;各组均继续培养48小时;
3,48小时后收集各组的细胞因子于-20℃冷冻保存,细胞使用PBS清洗后使用Trizol(Thermo 15596026)重悬,提取细胞中总RNA并逆转录为cDNA于-20℃保存(天根KR106);
4,通过QPCR(Promega A6002)检测各组细胞中促血管新生相关因子的表达量,包括血管内皮细胞生长因子(VEGF)、血管生成素1(Ang-1)、碱性成纤维细胞生长因子(bFGF)、肝细胞生长因子(HGF)引物序列如表3所示,结果如图6所示;
表3、促血管新生相关因子的检测引物
结果显示,血管新生相关基因(HGF、bFGF、VEGF、Ang-1)在低氧和RA、VB、VC刺激下相比常氧条件下均有高表达,但是HGF因检测背景值低,实际表达量可能低。
实施例6、不同刺激因子组合对VEGF、bFGF分泌量影响
1,选取P5代UC-MSC,消化后以2*105/cm2密度接种于6孔板中,使用无血清培养基培养,随机分为4组:
正常组置于普通二氧化碳培养箱中(5%CO2+20%O2)培养,
低氧组和预处理组置于低氧培养箱中培养(5%CO2+0.5%-10%O2);
预处理组分为:5uM全反式维甲酸(TARA)+5uM核黄素(VB2);5uM全反式维甲酸(TARA)+5uM核黄素(VB2)+50nM维生素A(Va)+1uM辅酶Q10。
2,24小时后更换培养基,每孔2ml,正常组使用无血清培养基正常培养,低氧组使用无血清培养基于低氧培养箱中培养,预处理组使用不同刺激因子预处理培养基于低氧培养箱中培养,各组均继续培养48小时;
3,48小时后收集各组的细胞因子于-20℃冷冻保存,细胞使用PBS清洗后使用Trizol(Thermo 15596026)重悬,提取细胞中总RNA并逆转录为cDNA于-20℃保存(天根KR106);
4,培养过程中,通过倒置显微镜(Motic AE2000)逐日观察各组细胞形态变化,结果如图7所示;
5,收集的细胞因子上清液使用Ellisa试剂盒检测各组细胞分泌的促血管新生的细胞因子,包括血管内皮细胞生长因子(VEGF)(欣博盛EHC108)和碱性成纤维细胞生长因子(bFGF)(酶免MM-0151H2),结果如图8所示。
结果显示,
(1)在低氧条件下以全反式维甲酸(TARA)+核黄素(VB2)为基础,分别添加维生素A(Va)和辅酶Q10,各组间细胞形态无明显改变;无明显细胞毒性
(2)刺激是必需的,刺激条件下VEGF分泌量比不刺激条件下有显著差异;全反式维甲酸(TARA)+核黄素(VB2)刺激和全反式维甲酸(TARA)+核黄素(VB2)+维生素A(Va)+辅酶Q10刺激无显著差异。
(3)bFGF是消化性因子,培养基中含量极高,培养细胞后含量降低;各种条件刺激下,bFGF含量无明显差异;进一步分析可见,多因子组合刺激下,对UC-MSC促血管新生相关细胞因子(尤其是bFGF)的影响,与单一因素刺激的结果(参见实施例5)有一定的差异。
最后需要说明的是,以上实施例仅用于帮助本领域技术人员了解本发明的实质,不用于限定本发明的保护范围。
Claims (8)
1.一种间充质干细胞(MSC)来源的促血管新生制剂的制备方法,所述方法包括如下步骤:
步骤(1),在无血清培养基中稳定培养间充质干细胞,优选的,所述的间充质干细胞为稳定穿代的脐带间充质干细胞(UC-MSC)细胞系;
步骤(2),使用细胞因子刺激制剂继续刺激培养所述稳定培养的间充质干细胞;
步骤(3),收集经步骤(2)培养的间充质干细胞的培养上清液;
步骤(4),浓缩所述的培养上清液得浓缩上清液,即为所述促血管新生制剂。
2.根据权利要求1所述的方法,其特征在于,步骤(2)所述的细胞因子刺激制剂为:在所述无血清培养基添加刺激因子配制,刺激因子由以下单个或多个组合而成:
全反式维甲酸(TARA),0.1mM-50mM,优选为1uM-200uM;
核黄素(VB2),0.05mM-50mM,优选为1uM-10uM;
抗坏血酸(Vc),0.1mM-100mM,优选为10uM-100uM;
维生素A(Va),0.01mM-50mM,优选为0.01uM-0.1uM;
辅酶Q10,0.05mM-50mM,优选为0.1uM-1uM。
3.根据权利要求1或2所述的方法,其特征在于,步骤(1)所述的稳定培养间充质干细胞的方法为:
MSC长至90%融合度时使用温和消化酶消化成单细胞,以活细胞数量按1-10*105/cm2的密度接种于经TC处理的培养皿中,使用无血清培养基置于低氧(0.5%-10%)培养箱中培养24小时。
4.根据权利要求1或2所述的方法,其特征在于,步骤(2)所述的刺激培养为:
1)细胞长至50%-70%融合度时,更换为预处理培养基(0.1-0.5ml/cm2);
2)更换为预处理培养基后置于低氧(0.5%-10%)培养箱中继续培养48小时。
5.根据权利要求1或2所述的方法,其特征在于,步骤(4)所述的浓缩所述的培养上清液为:使用超滤管离心浓缩5倍。
6.根据权利要求1所述的方法,其特征在于,所述的无血清培养基含量(mg/L)如下表所示:
优选的,所述的无血清培养基中,进一步包含:
重组人成纤维细胞生长因子(FGF),10mg/L;
重组人转化因子β(TGF-b),0.1mg/L;
重组人表皮生长因子(EGF),0.1mg/L。
7.使用权利要求1-6任一所述方法制备得到的促血管新生制剂。
8.权利要求1-6任一所述方法或权利要求7所述的制剂在制备药物中的应用,所述的药物包括但不限于:治疗移植物抗宿主疾病的药物、治疗抗溃疡性结肠炎的药物、治疗克罗恩病的药物、治疗骨关节炎的药物、用于心肌梗塞后心脏功能恢复的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210773047.6A CN115074321A (zh) | 2022-06-30 | 2022-06-30 | 一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210773047.6A CN115074321A (zh) | 2022-06-30 | 2022-06-30 | 一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115074321A true CN115074321A (zh) | 2022-09-20 |
Family
ID=83258393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210773047.6A Pending CN115074321A (zh) | 2022-06-30 | 2022-06-30 | 一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115074321A (zh) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101400787A (zh) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | 采用脂肪来源成体干细胞大量制造生长因子的方法 |
US20130177543A1 (en) * | 2011-12-20 | 2013-07-11 | Creative Medical Health Inc. | Natural Means of Augmenting Endogenous Stem Cell Numbers |
US20140178987A1 (en) * | 2012-12-20 | 2014-06-26 | Shanghai Tenth People's Hospital | Stem cell culture medium and its applications as well as a stem cell culture method |
WO2016009446A2 (en) * | 2014-07-14 | 2016-01-21 | Krishnan Venkataramanaa Neelam | A method for the regeneration and differentiation of human perinephric fat derived mesenchymal stromal cells into astroglial, renal, neuronal and pancreatic progenitor cells |
CN107043747A (zh) * | 2017-06-23 | 2017-08-15 | 王晓柯 | 一种人脐带间充质干细胞无血清培养基 |
KR20170116921A (ko) * | 2016-04-12 | 2017-10-20 | 서울대학교산학협력단 | 지방줄기세포에서 신경줄기세포, 신경세포 및 가바성 신경세포로의 분화 유도 방법 |
CN108251359A (zh) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | 一种间充质干细胞无血清培养基及培养方法 |
US20190117701A1 (en) * | 2016-04-27 | 2019-04-25 | Rohto Pharmaceutical Co., Ltd. | Mesenchymal stem cell expressing at least one cell surface marker selected from the group consisting of cd201, cd46, cd56, cd147, and cd165, method for preparing the same, pharmaceutical composition containing the mesenchymal stem cells, and method for preparing the same |
CN109852654A (zh) * | 2018-12-28 | 2019-06-07 | 广州润虹医药科技股份有限公司 | 能够诱导干细胞分泌细胞因子的组合物及其应用 |
CN110269833A (zh) * | 2019-06-05 | 2019-09-24 | 湖南丰晖生物科技有限公司 | 一种脐带间充质干细胞制剂及其制备方法和应用 |
CN110564680A (zh) * | 2019-08-27 | 2019-12-13 | 西安艾尔菲生物科技有限公司 | 人脐带间充质干细胞无血清培养基和制备方法及人脐带间充质干细胞无血清培养液获取方法 |
CN110894488A (zh) * | 2019-12-13 | 2020-03-20 | 深圳市蓝思人工智能医学研究院 | 全反式维甲酸在间充质干细胞分化调节中的应用 |
CN111235101A (zh) * | 2020-03-26 | 2020-06-05 | 于继莲 | 一种人脐带间充质干细胞培养基及人脐带间充质干细胞的培养方法 |
JP2021040551A (ja) * | 2019-09-11 | 2021-03-18 | 富士フイルム株式会社 | 培地組成物、キット、間葉系幹細胞組成物の製造方法、間葉系幹細胞組成物、間葉系幹細胞、細胞培養上清および細胞外小胞 |
CN114736853A (zh) * | 2022-04-02 | 2022-07-12 | 麦迪森(江苏)医学研究有限公司 | 一种增强间充质干细胞促血管新生能力的方法 |
-
2022
- 2022-06-30 CN CN202210773047.6A patent/CN115074321A/zh active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101400787A (zh) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | 采用脂肪来源成体干细胞大量制造生长因子的方法 |
US20130177543A1 (en) * | 2011-12-20 | 2013-07-11 | Creative Medical Health Inc. | Natural Means of Augmenting Endogenous Stem Cell Numbers |
US20140178987A1 (en) * | 2012-12-20 | 2014-06-26 | Shanghai Tenth People's Hospital | Stem cell culture medium and its applications as well as a stem cell culture method |
WO2016009446A2 (en) * | 2014-07-14 | 2016-01-21 | Krishnan Venkataramanaa Neelam | A method for the regeneration and differentiation of human perinephric fat derived mesenchymal stromal cells into astroglial, renal, neuronal and pancreatic progenitor cells |
KR20170116921A (ko) * | 2016-04-12 | 2017-10-20 | 서울대학교산학협력단 | 지방줄기세포에서 신경줄기세포, 신경세포 및 가바성 신경세포로의 분화 유도 방법 |
US20190117701A1 (en) * | 2016-04-27 | 2019-04-25 | Rohto Pharmaceutical Co., Ltd. | Mesenchymal stem cell expressing at least one cell surface marker selected from the group consisting of cd201, cd46, cd56, cd147, and cd165, method for preparing the same, pharmaceutical composition containing the mesenchymal stem cells, and method for preparing the same |
CN107043747A (zh) * | 2017-06-23 | 2017-08-15 | 王晓柯 | 一种人脐带间充质干细胞无血清培养基 |
CN108251359A (zh) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | 一种间充质干细胞无血清培养基及培养方法 |
CN109852654A (zh) * | 2018-12-28 | 2019-06-07 | 广州润虹医药科技股份有限公司 | 能够诱导干细胞分泌细胞因子的组合物及其应用 |
CN110269833A (zh) * | 2019-06-05 | 2019-09-24 | 湖南丰晖生物科技有限公司 | 一种脐带间充质干细胞制剂及其制备方法和应用 |
CN110564680A (zh) * | 2019-08-27 | 2019-12-13 | 西安艾尔菲生物科技有限公司 | 人脐带间充质干细胞无血清培养基和制备方法及人脐带间充质干细胞无血清培养液获取方法 |
JP2021040551A (ja) * | 2019-09-11 | 2021-03-18 | 富士フイルム株式会社 | 培地組成物、キット、間葉系幹細胞組成物の製造方法、間葉系幹細胞組成物、間葉系幹細胞、細胞培養上清および細胞外小胞 |
CN110894488A (zh) * | 2019-12-13 | 2020-03-20 | 深圳市蓝思人工智能医学研究院 | 全反式维甲酸在间充质干细胞分化调节中的应用 |
CN111235101A (zh) * | 2020-03-26 | 2020-06-05 | 于继莲 | 一种人脐带间充质干细胞培养基及人脐带间充质干细胞的培养方法 |
CN114736853A (zh) * | 2022-04-02 | 2022-07-12 | 麦迪森(江苏)医学研究有限公司 | 一种增强间充质干细胞促血管新生能力的方法 |
Non-Patent Citations (8)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108251359B (zh) | 一种间充质干细胞无血清培养基及培养方法 | |
CN112322580B (zh) | 一种间充质干细胞无血清培养基的应用 | |
Ji et al. | The differentiation of MSCs into functional hepatocyte-like cells in a liver biomatrix scaffold and their transplantation into liver-fibrotic mice | |
Antonitsis et al. | Cardiomyogenic potential of human adult bone marrow mesenchymal stem cells in vitro | |
Domouky et al. | Mesenchymal stem cells and differentiated insulin producing cells are new horizons for pancreatic regeneration in type I diabetes mellitus | |
US11339372B2 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
KR20140000945A (ko) | 고농도의 줄기세포 제조방법 | |
WO2015042356A1 (en) | Chemically defined culture medium for stem cell maintenance and differentiation | |
CN114736853A (zh) | 一种增强间充质干细胞促血管新生能力的方法 | |
JP2023134442A (ja) | 心外傷後の心機能を増強することができる皮質骨幹細胞由来のエキソソーム | |
CN110713984B (zh) | 诱导人间充质干细胞生成功能内皮细胞的方法 | |
CN102899288B (zh) | 一种人胰岛来源的胰腺干细胞系的构建及向胰岛素分泌细胞分化的方法 | |
Unser et al. | 3D brown adipogenesis to create “Brown-Fat-in-Microstrands” | |
CN113943699B (zh) | 对抗高糖损伤的脐带间充质干细胞诱导液、方法及应用 | |
CN113943701A (zh) | 一种可扩增间充质干细胞的无血清培养基及其制备方法 | |
CN109735491A (zh) | 一种可扩增造血干细胞的无血清培养基及其制备方法 | |
Nasser et al. | Current situation and future of stem cells in cardiovascular medicine | |
CN112522178B (zh) | 一种在体外长期培养和扩增成熟肝细胞的方法 | |
US20170112879A1 (en) | Methods of protection against ischemia reperfusion injury | |
CN105062952A (zh) | 间充质干细胞转化为胰岛细胞的方法 | |
WO2006073692A2 (en) | Isolation and purification of human insulin producing cells for the treatment of insulin dependent diabetes | |
CN115074321A (zh) | 一种间充质干细胞(msc)来源的促血管新生的制剂及其制备方法 | |
CN106754650A (zh) | 一种骨髓来源的内皮祖细胞培养方法 | |
CN115369077B (zh) | Meflc细胞株及其构建方法和应用 | |
CN106474157B (zh) | 一种肝干细胞注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220920 |